

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 899 263 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
03.03.1999 Bulletin 1999/09

(21) Application number: 98115258.0

(22) Date of filing: 13.08.1998

(51) Int. Cl.⁶: C07D 239/95, A61K 31/505,
C07D 409/12, C07D 401/12,
C07D 495/04

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 13.08.1997 JP 218767/97
13.08.1997 JP 218768/97

(71) Applicant: Fujirebio Inc.
Chuo-ku, Tokyo (JP)


(72) Inventors:
• Nakashima, Yoshiharu
Chuo-ku, Tokyo (JP)

• Fujita, Takashi
Chuo-ku, Tokyo (JP)
• Hizuka, Michiyo
Chuo-ku, Tokyo (JP)
• Ikawa, Hiroshi
Chuo-ku, Tokyo (JP)
• Hiruma, Toru
Chuo-ku, Tokyo (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)


(54) Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration

(57) A pyrimidine nucleus-containing compound represented by the formula (I):




(I)

wherein ring A represents the ring of the formula (a):



(a)



(b)

in which R^{1'} is the group such as an alkyl group or an alkenyl group; R² to R⁵ independently represent the group such as an alkyl group or an alkenyl group; with the proviso that at least one of R² to R⁵ is an alkenyl group, or acid addition salts thereof.

in which R¹ is a nitro group, an amino group, a substituted amino group or a halogen atom, or the ring of the formula (b):

EP 0 899 263 A2